To amend the Federal Food, Drug, and Cosmetic Act to authorize the use of investigational individualized medical treatments by patients diagnosed with a life-threatening disease or condition or severely debilitating illness, and for other purposes.

Latest action: Referred to the House Committee on Energy and Commerce. · Jun 8, 2026

View full text on Congress.gov ↗